screening all – A German 10-year study found that screening more than 220,000 children identified 590 youngsters already in the early stages of type 1 diabetes. Crucially, 212 of 260 children who later developed the disease had been flagged by broad screening—even though 90%
On a blood test. there’s a window where type 1 diabetes hasn’t yet become the life-threatening illness most families fear—when the immune system has started targeting the pancreas. but glucose levels still look normal. The trouble is that early stages of the disease are symptom-free. so many children don’t know anything is happening until a crisis.
That’s the gap a new German study tried to close, and it found that widening screening beyond family history can catch more children earlier than current practice in the United States.
In the United States. people are routinely screened only if they have family members with type 1 diabetes or a known genetic risk. But researchers reviewing results from a 10-year study in Germany report in the Journal of the American Medical Association (May 21) that extending screening identified more children without a family history. About 90 percent of people who develop type 1 diabetes do not have family members with the disease.
The team screened more than 220,000 children and found 590 were in the early stages of the disease. Of the 260 children who went on to develop type 1 diabetes in the follow-up period, 212—81 percent—had been tagged by screening. When researchers recalculated the numbers as if screening had been restricted to those with a family history. only 101 of the 590 early-stage children would have been identified. and only 34 of the 212 who progressed to type 1 diabetes.
That difference matters because early diagnosis is not just about numbers on a chart. Jennifer Sherr, a pediatric endocrinologist at Yale School of Medicine who was not involved in the new study, said knowing the diagnosis is coming can help people prepare for what life will be.
She’s also pointing to a concrete medical reason to find the disease earlier. A medication called teplizumab can delay the onset of type 1 diabetes for people in an early stage. Type 1 diabetes is an autoimmune disease in which the body destroys beta cells in the pancreas that produce insulin. Insulin regulates blood sugar glucose, which is the body’s main source of fuel. Managing the disease requires individuals to monitor blood sugar and inject multiple, varying doses of insulin throughout the day.
Close to 4 in 1,000 children in the United States report having the disease.
The early stages are different from the diagnosis most people imagine. In stage 1, the body has begun destroying beta cells, but blood glucose levels are still normal. A blood test positive for two or more proteins called autoantibodies—proteins that wrongly target beta cells—confirms this first stage. If a person tests positive for two or more autoantibodies plus blood glucose levels are becoming abnormal. the individual is at stage 2. For children in these early stages. there is an 85 percent or higher risk of ending up with type 1 diabetes. or stage 3. within 15 years. Progression from early stages to the clinical disease happens more quickly in children than in adults.
By the time many children are diagnosed, symptoms are already present and many beta cells have already been lost. Often. diagnosis occurs because of a medical emergency: diabetic ketoacidosis. a life-threatening situation in which insulin is so low it’s not possible for the body to access glucose for energy. Blood sugar spikes and acids accumulate in the blood as the body turns to breaking down fats. Symptoms include shortness of breath, feeling thirsty, confusion, and vomiting; without treatment, a person can become comatose and die.
For 30 to 40 percent of children in the United States, diagnosis happens because they develop diabetic ketoacidosis.
The German study also tracked something else that makes the numbers feel less abstract. The researchers reported that the rate at which children with early stages progressed to clinical disease was the same whether they had family members with type 1 diabetes or not.
In Bavaria, the new study screened and followed up preschool- and elementary school–aged children from 2015 to 2025. Families of children identified as having early stage disease had access to diabetes education and monitoring at diabetes centers. That setup matters because knowing whether an individual is in the early stages means monitoring and treatment can begin early. which can make it possible to avoid diabetic ketoacidosis. Past research has found that having this condition at the time of diagnosis is linked to poorer control of the disease for children and teens.
Teplizumab is approved for children and adults in stage 2. The medication is given as a 14-day infusion treatment. In a study of children and adults reported in 2019 in the New England Journal of Medicine. teplizumab delayed progression to clinical type 1 diabetes by around four years compared with around two years in the placebo group. Sherr said that delay can allow a young child to get a little bit older before needing insulin. or before having to start in “the middle of teenage years” and in a time to “grapple with adolescence itself.” She added. “It’s amazing to think about having that time” before taking on the burden of regular treatment.
In the United States, the question now is whether screening should follow the same logic—whether health systems should look beyond risk factors in the family tree. There are studies testing implementation of general population screening for type 1 diabetes in the Dakotas and Colorado.
The German findings don’t argue that screening is optional when it comes to the people most likely to be caught. They show what happens when you broaden the net: 212 children who later developed type 1 diabetes were identified by screening even though they had no family history—precisely the group that makes up the majority of all future patients.
type 1 diabetes screening teplizumab early stages stage 1 stage 2 stage 3 diabetic ketoacidosis autoantibodies preschool and elementary school children Bavaria study JAMA May 21
So… they’re just testing kids for diabetes now?
This sounds good on paper but I feel like blood tests on every kid is a lot. Like what if it scares parents for nothing? Also doesn’t type 1 not show glucose until later or something??
Wait so they caught 590 early stages and later 212 still got it? That’s like… almost everyone? Idk I’m confused. But if symptoms are none until it’s a crisis, I guess screening helps? Germany does it so maybe America should too but healthcare here will never agree on cost.
I read this too fast and thought it said screening for ALL kids would prevent type 1, but it’s more like catching early immune stuff? Either way, the whole “90% on a blood test” part makes me worry they’ll misread results and start treatments too soon. Plus family history screening is already a thing, so how is “more screening” not just more bills and false alarms?